The US Food and Drug Administration (FDA) has approved a blood-based screening method for CRC that detects methylation of Septin9, a plasma biomarker of CRC, with early CRC sensitivity and specificity of 59% and 79%, respectively [16]. Here, SEPTIN9 is linked to colorectal carcinoma.